Refine by
Oncology Patient Articles & Analysis
43 news found
Medical science is witnessing remarkable advancements in neurology and oncology, with cutting-edge technologies shaping the future of patient care. ...
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon Biosystems, a pioneer of liquid biopsy ...
“The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments.” Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, “Leaps by Bayer was founded to help solve ten of the world’s biggest ...
ByBayer AG
This Phase 3 programme is expected to include up to 2,000 patients and deliver a comprehensive data set supporting a clinical endpoint in Surgical Site Infection (“SSI”) reduction that is clinically and statistically significant. ...
Oncology informatics company, Inspirata, is pleased to announce the recent addition of a new key member to the company’s leadership team. ...
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, is conducting a Non-Small Cell Lung Cancer (NSCLC) study at the esteemed Johns Hopkins University. ...
BAT-90 BetaGlue has developed and patented BAT-90 ("Beta Ablation Therapy with Yttrium-90"), consisting of a p radiation-emitting biocompatible matrix, delivered to patients via percutaneous injection or during surgery: the Yttrium-90-labelled microspheres present inside the matrix are injected into the tumour and, as the carrier need few seconds to reach full polymerisation, ...
Representing a total $140M USD investment into the area, Bayer’s 62,100-square-foot building houses a new center of precision molecular oncology research equipped with state-of-the-art laboratories and offices for the development of novel targeted cancer therapies for patients. ...
ByBayer AG
It has the potential to revolutionize radiation oncology, having demonstrated compelling success in some of the most difficult-to-treat cancers and in treating patients for whom all other treatment options have been exhausted. ...
It has the potential to revolutionize radiation oncology, having demonstrated compelling success in some of the most difficult-to-treat cancers and in treating patients for whom all other treatment options have been exhausted. ...
FDA for the reduction of SOM induced by radiotherapy, and we look forward to submitting a New Drug Application to the FDA by year end in order to bring this potential treatment to patients as quickly as possible.” Results from the 455-patient Phase 3 trial demonstrated a meaningful reduction in patients’ SOM burden across multiple ...
In the US, we anticipate that the largest oncology network will provide one of the first sites to treat patients and that a second oncology network in the US may participate along side. We believe that the participation of clinical trial networks focused on cancer treatment will help to increase the enrollment rate in FLAMINGO-01 and expand the ...
PPP004 was developed to help manage pain and itch in patients with EB and promote wound healing. PPP004 containing CBD only has been granted ODD by both the U.S. ...
True North and its partners supply value priced CBD bulk ingredients to licensed producers across Canada, and deliver a range of extracted and edible CBD products to patients and consumers alike through the True North brand. For more information, please visit www.truenorthcannabis.com. ...
Most other biosimilar treatments, particularly in oncology, create a high-cost burden on the payer or patient and often are inaccessible to patients in need of this critical treatment. ...
Guardant360 TissueNext is the company’s first tissue-based test to help oncologists identify patients with advanced cancer who may benefit from biomarker-informed treatment. The policy covers Guardant360 TissueNext for Medicare fee-for-service patients with advanced solid tumor cancers as a standalone service. “We are pleased that Medicare has taken ...
For more information: www.chumontreal.qc.ca/crchum and @CRCHUM About Tetra Bio-Pharma Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their ...
The abstract titled “The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device” analyzes data collected using both SOZO and DXA in healthy participants and cancer patients. ...
About Tetra Bio-Pharma Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has enabled them to develop a pipeline ...
“This broad partnership will tap into our portfolio of end to end solutions to generate meaningful evidence and help optimize Lilly’s therapy development, and ultimately bring more targeted treatment options to cancer patients.” “We are pleased to collaborate with a widely-utilized and experienced laboratory like Foundation Medicine to ensure broad access ...